Comment to study: A randomized phase |III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild type (WT) KRAS metastatic colorectal cancer (mCRC) patients: German study AIO KRK-0306(FIRE-3)
2013
Abstract
Therapy development in metastatic colorectal cancer and its influence for overal survival prolongation, history of discovering ras oncogene and its predictive role in effectivness antiEGFR therapy, with respect to revision of the results of earlier published clinical studies with antiEGFR therapy in mCRC.